Skip to main content
Livermore
Livermore
ZHEN

683 Capital Management, LLC

SEC CIK
0001404574
Latest filing
Aug 14, 2026

The latest 13F from 683 Capital Management, LLC covers Q2 2026 (filed Aug 14, 2026): 128 long positions worth $1.09B. The top 10 holdings make up 39.1% of the portfolio, and the largest is Capital One Financial Corp (COF) at 6.7%. Livermore has 22 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q2 2026

Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
17
Est. +$84.4M
Added
28
Est. +$67.8M
Reduced
39
Est. −$116.4M
Sold out
97
Est. −$157.6M

Top 5 holdings

Share of this quarter's portfolio value

  1. COFCapital One Financial Corp
    6.7%$73.2MHistory
  2. CVNACarvana Co.
    4.5%$49.4MHistory
  3. ANABAnaptysbio, Inc
    4.1%$44.6MHistory
  4. KSPIJoint Stock Co Kaspi.kz
    3.7%$40.7MHistory
  5. BridgeBio Pharma, Inc.10806XAB8
    3.6%$38.8M

Biggest buys

New and added positions, by estimated amount bought

  1. UUnity Software Inc.
    +$17.6MNewHistory
  2. TRAXFirst Tracks Biotherapeutics, Inc.
    +$15.1MNewHistory
  3. SESea Ltd
    +$12.9MNewHistory
  4. HRMYHarmony Biosciences Holdings, Inc.
    +$10.7MNewHistory
  5. NUNu Holdings Ltd.
    +$10.0MNewHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. QUREuniQure N.V.
    +1.68 pp0.8% → 2.4%History
  2. UUnity Software Inc.
    +1.62 pp0.0% → 1.6%History
  3. MOHMolina Healthcare, Inc.
    +1.49 pp2.0% → 3.5%History
  4. TRAXFirst Tracks Biotherapeutics, Inc.
    +1.39 pp0.0% → 1.4%History
  5. SESea Ltd
    +1.19 pp0.0% → 1.2%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. ASTHAstrana Health, Inc.
    −$22.7MReducedHistory
  2. GXOGXO Logistics, Inc.
    −$14.4MReducedHistory
  3. LLYEli Lilly & Co
    −$13.8MSold outHistory
  4. FOLDAmicus Therapeutics, Inc.
    −$11.2MSold outHistory
  5. TGTXTG Therapeutics, Inc.
    −$11.0MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. GXOGXO Logistics, Inc.
    −1.40 pp2.4% → 1.0%History
  2. LLYEli Lilly & Co
    −1.28 pp1.3% → 0.0%History
  3. FOLDAmicus Therapeutics, Inc.
    −1.04 pp1.0% → 0.0%History
  4. Gossamer Bio, Inc.38341PAA0
    −0.98 pp1.0% → 0.0%
  5. APLSApellis Pharmaceuticals, Inc.
    −0.93 pp0.9% → 0.0%History

Metrics

13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$1.09B
+$9.22M (+0.9%) vs. prior quarter
Positions
128
−80 vs. prior quarter
Top 10 concentration
39.1%
Top 10 as share of value
Turnover
14.1%
Q2 2026, one quarter
Average holding period
9.0 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $2.10B (Q4 2021)

Q1 2021: $1.55BQ2 2021: $2.01BQ3 2021: $1.93BQ4 2021: $2.10BQ1 2022: $1.69BQ2 2022: $1.38BQ3 2022: $1.24BQ4 2022: $1.11BQ1 2023: $1.12BQ2 2023: $1.03BQ3 2023: $986.6MQ4 2023: $998.8MQ1 2024: $980.6MQ2 2024: $953.5MQ3 2024: $981.8MQ4 2024: $1.02BQ1 2025: $985.8MQ2 2025: $986.1MQ3 2025: $1.10BQ4 2025: $1.20BQ1 2026: $1.08BQ2 2026: $1.09B
Q1 2021Q2 2026
13F filings of 683 Capital Management, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q2 2026Aug 14, 2026128$1.09BCOFCVNAANABvs. Q1 2026SEC
Q1 2026May 15, 2026208$1.08BCOFCVNABridgeBio Pharma, Inc.vs. Q4 2025SEC
Q4 2025Feb 17, 2026205$1.20BCOFWVECVNAvs. Q3 2025SEC
Q3 2025Nov 14, 2025117$1.10BCOFQURECVNAvs. Q2 2025SEC
Q2 2025Aug 14, 2025116$986.1MCOFCVNAGXOvs. Q1 2025SEC
Q1 2025May 15, 2025119$985.8MCOFGXOINSMED Incvs. Q4 2024SEC
Q4 2024Feb 14, 2025210$1.02BCOFWVECVNAvs. Q3 2024SEC
Q3 2024Nov 14, 2024129$981.8MCOFEROHGVvs. Q2 2024SEC
Q2 2024Aug 14, 2024131$953.5MHGVCOFSNvs. Q1 2024SEC
Q1 2024May 15, 2024122$980.6MHGVCOFEROvs. Q4 2023SEC
Q4 2023Feb 14, 2024240$998.8MBWACOFEROvs. Q3 2023SEC
Q3 2023Nov 14, 2023135$986.6MENVAEROCOFvs. Q2 2023SEC
Q2 2023Aug 14, 2023144$1.03BENVAEROCOFvs. Q1 2023SEC
Q1 2023May 15, 2023271$1.12BENVAEROOccidental Pete Corp WT Exp 080327vs. Q4 2022SEC
Q4 2022Feb 14, 2023297$1.11BENVAEROWVEvs. Q3 2022SEC
Q3 2022Nov 14, 2022240$1.24BENVAEROPPLIvs. Q2 2022SEC
Q2 2022Aug 15, 2022268$1.38BENVAPPLIOPENvs. Q1 2022SEC
Q1 2022May 16, 2022348$1.69BENVACVNACDLXvs. Q4 2021SEC
Q4 2021Feb 14, 2022335$2.10BCVNAENVAOPENvs. Q3 2021SEC
Q3 2021Nov 15, 2021206$1.93BCVNACDLXENVAvs. Q2 2021SEC
Q2 2021Aug 16, 2021186$2.01BCVNACDLXFEvs. Q1 2021SEC
Q1 2021May 17, 2021151$1.55BCVNAENVAFE–SEC

13D and 13G filings

Companies where 683 Capital Management, LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

5 companies, largest stake first.

Companies where 683 Capital Management, LLC owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
RNAQRainier Acquisition Corp13G11.20%862.5K shares0.00 ppfrom 11.20%Sep 3, 20262 filingsSep 3, 2026SEC
GOSSGossamer Bio, Inc.13G9.99%49.9M shares+6.09 ppfrom 3.90%Mar 2, 20263 filingsJun 11, 2026SEC
MREOMereo BioPharma Group plc13G8.18%65.1M sharesNewJan 6, 20261 filingJan 6, 2026SEC
INABIN8BIO, Inc.13G7.86%770.4K sharesNewDec 30, 20251 filingDec 30, 2025SEC
IMUXImmunic, Inc.13G/A5.90%7.50M shares−4.00 ppfrom 9.90%Aug 8, 20252 filingsFeb 17, 2026SEC

Latest filings

140 filings on file made by 683 Capital Management, LLC or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by 683 Capital Management, LLC
CompanyFiled (ET)FormStakeChangeEvent dateFiling
RNAQRainier Acquisition CorpSep 3, 20265:55 PM ET13G11.20%862.5K shares0.00 ppfrom 11.20%Aug 27, 2026SEC
RNAQRainier Acquisition CorpSep 3, 20265:53 PM ET13G11.20%862.5K sharesNewAug 27, 2026SEC
FRNMFreenome, Inc.Aug 12, 202611:13 AM ET13G/A0.00%0 shares−7.19 ppfrom 7.19%Below 5%Jun 30, 2026SEC
GOSSGossamer Bio, Inc.Jun 11, 20264:54 PM ET13G9.99%49.9M shares+6.09 ppfrom 3.90%Jun 4, 2026SEC
IMUXImmunic, Inc.May 15, 202610:48 AM ET13G/A3.40%474.2K shares–Below 5%Mar 31, 2026SEC
MODDModular Medical, Inc.May 15, 202610:26 AM ET13G/A4.67%259.2K shares−0.85 ppfrom 5.52%Below 5%Mar 31, 2026SEC
MRSNMersana Therapeutics, Inc.May 15, 202610:25 AM ET13G/A0.00%0 shares−7.03 ppfrom 7.03%Below 5%Mar 31, 2026SEC
GUTSFractyl Health, Inc.May 15, 202610:24 AM ET13G/A4.81%7.68M shares−0.52 ppfrom 5.33%Below 5%Mar 31, 2026SEC
GOSSGossamer Bio, Inc.Mar 24, 20264:48 PM ET13G/A3.90%9.33M shares−1.33 ppfrom 5.23%Below 5%Mar 18, 2026SEC
MODDModular Medical, Inc.Mar 10, 20264:56 PM ET13G5.52%8.28M shares+2.22 ppfrom 3.30%Mar 3, 2026SEC
GOSSGossamer Bio, Inc.Mar 2, 202611:57 AM ET13G5.23%12.3M sharesNewFeb 23, 2026SEC
RVPHReviva Pharmaceuticals Holdings, Inc.Feb 17, 20264:19 PM ET13G/A3.00%3.49M shares−2.36 ppfrom 5.36%Below 5%Dec 31, 2025SEC
IMUXImmunic, Inc.Feb 17, 20264:18 PM ET13G/A5.90%7.50M shares−4.00 ppfrom 9.90%Dec 31, 2025SEC
MRSNMersana Therapeutics, Inc.Feb 17, 202610:09 AM ET13G/A7.03%351.3K shares+1.56 ppfrom 5.47%Dec 31, 2025SEC
FRNMFreenome, Inc.Feb 17, 202610:08 AM ET13G/A7.19%640.9K shares–Dec 31, 2025SEC
MREOMereo BioPharma Group plcJan 6, 20265:38 PM ET13G8.18%65.1M sharesNewDec 29, 2025SEC
INABIN8BIO, Inc.Dec 30, 20251:56 PM ET13G7.86%770.4K sharesNewDec 22, 2025SEC
MRSNMersana Therapeutics, Inc.Nov 24, 20255:12 PM ET13G5.47%273.4K sharesNewNov 17, 2025SEC
MODDModular Medical, Inc.Nov 14, 202512:26 PM ET13G/A3.30%1.87M shares−3.10 ppfrom 6.40%Below 5%Aug 14, 2025SEC
INSEInspired Entertainment, Inc.Nov 14, 202512:24 PM ET13G/A4.20%1.13M shares−2.20 ppfrom 6.40%Below 5%Jul 2, 2025SEC